Literature DB >> 9428231

Down-regulation of hepatic and renal 11 beta-hydroxysteroid dehydrogenase in rats with liver cirrhosis.

G Escher1, A Nawrocki, T Staub, B S Vishwanath, B M Frey, J Reichen, F J Frey.   

Abstract

BACKGROUND & AIMS: 11 beta-Hydroxysteroid dehydrogenase (11 beta-OHSD) enzymes are responsible for the interconversion of active 11 beta-hydroxycorticosteroids into inactive 11-ketoglucocorticosteroids and by that mechanism regulate the intracellular access of the steroids to the cognate receptor. A down-regulation of the shuttle of active to inactive glucocorticoids enhances access of glucocorticosteroids to both the glucocorticoid and the mineralocorticoid receptors. In liver cirrhosis, enhanced mineralocorticoid and glucocorticoid effects are observed. We therefore investigated the impact of liver cirrhosis after bile duct ligation on the transcription and activity of 11 beta-OHSD1 and 11 beta-OHSD2 in the corresponding tissues.
METHODS: Messenger RNA from 11 beta-OHSD1 and 11 beta-OHSD2 was assessed by reverse-transcription polymerase chain reaction; activity was assessed by measuring the interconversion of corticosterone to dehydrocorticosterone. The effect of bile and bile salts was determined using COS-1 cells transfected with 11 beta-OHSD1 or 11 beta-OHSD2.
RESULTS: In liver tissue, the messenger RNA ratios of 11 beta-OHSD1 to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels and, in kidney tissue, the ratios of 11 beta-OHSD2 to GAPDH levels decreased after induction of liver cirrhosis. The 11 beta-OHSD activities were correspondingly reduced. Bile and individual bile salts inhibited 11 beta-OHSD1 and 11 beta-OHSD2 oxidative activity in transfected COS-1 cells.
CONCLUSIONS: These findings indicate that in liver cirrhosis the mineralocorticoid and glucocorticoid receptor-protecting effects by the 11 beta-OHSD isoenzymes are down-regulated and that by the same mechanism the glucocorticoid and mineralocorticoid effects are enhanced.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9428231     DOI: 10.1016/s0016-5085(98)70645-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  9 in total

1.  Reduced activity of 11 beta-hydroxysteroid dehydrogenase in patients with cholestasis.

Authors:  C Quattropani; B Vogt; A Odermatt; B Dick; B M Frey; F J Frey
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

2.  Effect of angiotensin II on rat renal cortical 11beta-hydroxysteroid dehydrogenase.

Authors:  M A Fischer; P M Schiffers; H A Struijker-Boudier
Journal:  Endocrine       Date:  2000-12       Impact factor: 3.633

3.  Natriuretic and aquaretic effects of intravenously infused calcium in preascitic human cirrhosis: physiopathological and clinical implications.

Authors:  G Sansoè; F Wong
Journal:  Gut       Date:  2007-02-15       Impact factor: 23.059

4.  Semi-automated approach for generation of biological networks on drug-induced cholestasis, steatosis, hepatitis, and cirrhosis.

Authors:  Hyun Kil Shin; Oana Florean; Barry Hardy; Tatyana Doktorova; Myung-Gyun Kang
Journal:  Toxicol Res       Date:  2022-03-03

5.  Bile acids modulate glucocorticoid metabolism and the hypothalamic-pituitary-adrenal axis in obstructive jaundice.

Authors:  Alison D McNeilly; David P Macfarlane; Emmett O'Flaherty; Dawn E Livingstone; Tijana Mitić; Kirsty M McConnell; Scott M McKenzie; Eleanor Davies; Rebecca M Reynolds; Helle C Thiesson; Ole Skøtt; Brian R Walker; Ruth Andrew
Journal:  J Hepatol       Date:  2010-03-04       Impact factor: 25.083

Review 6.  11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.

Authors:  Karen Chapman; Megan Holmes; Jonathan Seckl
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

Review 7.  Dysregulation of ENaC in Animal Models of Nephrotic Syndrome and Liver Cirrhosis.

Authors:  Soo Wan Kim
Journal:  Electrolyte Blood Press       Date:  2006-03

8.  Hypercortisolism in patients with cholestasis is associated with disease severity.

Authors:  Verena Theiler-Schwetz; Hansjörg Schlager; Barbara Obermayer-Pietsch; Tatjana Stojakovic; Günter Fauler; Peter Fickert; Gernot Zollner
Journal:  BMC Gastroenterol       Date:  2021-12-07       Impact factor: 3.067

Review 9.  Adrenal Insufficiency in Cirrhosis.

Authors:  Brian J Wentworth; Helmy M Siragy
Journal:  J Endocr Soc       Date:  2022-07-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.